Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
National University Hospital, Singapore
Spanish Breast Cancer Research Group
Mayo Clinic
University of Miami
Lund University Hospital
ABL Bio, Inc.
Fudan University
Bristol-Myers Squibb
EpicentRx, Inc.
Guangdong Provincial People's Hospital
Fudan University
University of Wisconsin, Madison
Yonsei University
Green3Bio, Inc.
Vall d'Hebron Institute of Oncology
The Methodist Hospital Research Institute
Morphotek
Calithera Biosciences, Inc
Sun Yat-sen University
Centre Hospitalier Universitaire de Besancon
Hallym University Medical Center
Sun Yat-sen University
University of Pisa
Masonic Cancer Center, University of Minnesota
Peregrine Pharmaceuticals
Hoffmann-La Roche
Peregrine Pharmaceuticals
Shanghai Gynecologic Oncology Group
Eli Lilly and Company
Hoffmann-La Roche
Bayer
Biogen
GBG Forschungs GmbH
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb